AU2022202403A1 - Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders - Google Patents

Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders

Info

Publication number
AU2022202403A1
AU2022202403A1 AU2022202403A AU2022202403A AU2022202403A1 AU 2022202403 A1 AU2022202403 A1 AU 2022202403A1 AU 2022202403 A AU2022202403 A AU 2022202403A AU 2022202403 A AU2022202403 A AU 2022202403A AU 2022202403 A1 AU2022202403 A1 AU 2022202403A1
Authority
AU
Australia
Prior art keywords
heteroary
medicinal
disorders
aryl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2022202403A
Other versions
AU2022202403B2 (en
Inventor
Atul Agarwal
Joel Charles Barrish
Dawei Chen
Milind Deshpande
Kyle J. Eastman
Venkat Rao GADHACHANDA
William Greenlee
Akihiro Hashimoto
Godwin Pais
Avinash S. Phadke
Qiuping Wang
Xiangzhu Wang
Jason Allan Wiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/020528 external-priority patent/WO2018160889A1/en
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Priority to AU2022202403A priority Critical patent/AU2022202403B2/en
Publication of AU2022202403A1 publication Critical patent/AU2022202403A1/en
Application granted granted Critical
Publication of AU2022202403B2 publication Critical patent/AU2022202403B2/en
Priority to AU2024201826A priority patent/AU2024201826A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2022202403A 2017-03-01 2022-04-12 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders Active AU2022202403B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022202403A AU2022202403B2 (en) 2017-03-01 2022-04-12 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders
AU2024201826A AU2024201826A1 (en) 2017-03-01 2024-03-20 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medical Disorders

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465782P 2017-03-01 2017-03-01
US62/465,782 2017-03-01
US201762466301P 2017-03-02 2017-03-02
US62/466,301 2017-03-02
PCT/US2018/020528 WO2018160889A1 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
AU2018227849A AU2018227849B2 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
AU2022202403A AU2022202403B2 (en) 2017-03-01 2022-04-12 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2018227849A Division AU2018227849B2 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201826A Division AU2024201826A1 (en) 2017-03-01 2024-03-20 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medical Disorders

Publications (2)

Publication Number Publication Date
AU2022202403A1 true AU2022202403A1 (en) 2022-05-05
AU2022202403B2 AU2022202403B2 (en) 2024-02-01

Family

ID=63370540

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018227849A Active AU2018227849B2 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
AU2022202403A Active AU2022202403B2 (en) 2017-03-01 2022-04-12 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders
AU2024201826A Pending AU2024201826A1 (en) 2017-03-01 2024-03-20 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medical Disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2018227849A Active AU2018227849B2 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201826A Pending AU2024201826A1 (en) 2017-03-01 2024-03-20 Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medical Disorders

Country Status (10)

Country Link
US (3) US11084800B2 (en)
EP (2) EP3985002A1 (en)
JP (3) JP7133561B2 (en)
KR (2) KR102632860B1 (en)
CN (1) CN110603252A (en)
AU (3) AU2018227849B2 (en)
CA (1) CA3053818A1 (en)
IL (3) IL294069B2 (en)
MX (2) MX2019010381A (en)
WO (1) WO2018160889A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
ES2933513T3 (en) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Macrocyclic compounds for the treatment of medical disorders
AU2019239952A1 (en) * 2018-03-20 2020-10-08 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020041100A1 (en) * 2018-08-22 2020-02-27 Merck Sharp & Dohme Corp. Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (en) * 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
CN113195472A (en) 2018-12-17 2021-07-30 艾其林医药公司 Targeted drug delivery for the treatment of complement-mediated disorders
CN111487398B (en) * 2019-01-25 2022-11-11 四川大学华西医院 Biomarkers for hemangioma treatment
CA3147005A1 (en) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CN115362162A (en) * 2020-02-20 2022-11-18 艾其林医药公司 Heteroaryl compounds for the treatment of complement factor D mediated disorders
CN111592557A (en) * 2020-05-09 2020-08-28 河北合佳医药科技集团股份有限公司 One-step environment-friendly preparation method of 7-amino-3-vinyl cephalosporanic acid
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2024008121A1 (en) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 Difluoro-substituted azabicyclo compounds and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
CA2248772C (en) 1996-03-13 2007-06-12 John D. Lambris Novel peptides which inhibit complement activation
WO1998055471A1 (en) * 1997-06-03 1998-12-10 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
RU2202344C2 (en) 1998-03-26 2003-04-20 Джапан Тобакко Инк. Nociceptine antagonists, amide derivatives, analgetic agent, method of initiation of antagonistic effect to nociceptine, method of pain treatment, pharmaceutical compositions
CN1215076C (en) 1998-09-09 2005-08-17 症变治疗公司 Heteroaromatic inhibitors of fructose 1,6-bisphosphatase
KR20000047461A (en) 1998-12-29 2000-07-25 성재갑 Thrombin inhibitors
EP1219611A4 (en) 1999-09-03 2003-03-19 Ajinomoto Kk Novel processes for preparing oxazepine derivatives
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
CN100354276C (en) 2002-07-16 2007-12-12 阿姆拉医疗有限公司 Biologically active compounds
EP2311479B1 (en) 2002-09-20 2014-07-23 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
FR2845382A1 (en) 2002-10-02 2004-04-09 Sanofi Synthelabo INDAZOLECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
BRPI0506629A (en) 2004-02-10 2007-05-02 Univ Colorado factor b inhibition, the alternative complement system pathway and related methods
CN1938293A (en) 2004-03-24 2007-03-28 捷瑞尼股份公司 New compounds for the inhibition of angiogenesis and use of thereof
SI1755616T1 (en) 2004-04-08 2014-04-30 Eye Co Pty Ltd. Treatment of exudative retinopathy with mineralcorticoids
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2390828T3 (en) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Powerful compstatin analogues
KR20080075909A (en) 2005-12-12 2008-08-19 제네랩스 테크놀로지스, 인코포레이티드 N-(6-membered aromatic ring)-amido anti-viral compounds
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2008047831A1 (en) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
ES2397292T3 (en) 2007-01-15 2013-03-06 Santen Pharmaceutical Co., Ltd New indole derivative that has kinase I B inhibitory activity
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
EP2238142B1 (en) 2007-12-24 2012-07-04 Janssen R&D Ireland Macrocyclic indoles as hepatitis c virus inhibitors
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
MX356218B (en) 2008-08-05 2018-05-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c5.
PT2424557T (en) 2009-05-01 2018-02-05 Univ Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
EP2490026A4 (en) 2009-10-16 2013-08-21 Mochida Pharm Co Ltd Marker associated with non-alcoholic steatohepatitis
MX2012005151A (en) 2009-11-05 2012-08-23 Federico Ii University Of Naples Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis.
RS61281B1 (en) 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors
CN102939282B (en) 2010-04-16 2015-12-02 Ac免疫有限公司 Be used for the treatment of the compound of the disease relevant with amyloid or amyloid-like protein
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
JP6522337B2 (en) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Cell-reactive, long-acting or targeted compstatin analogues and uses thereof
AP2013007263A0 (en) 2011-05-27 2013-11-30 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections
WO2012177782A1 (en) 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
JP6618682B2 (en) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Treatment of chronic disorders with complement inhibitors
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
CN110229216B (en) 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 Compstatin peptides with improved pharmacokinetic properties
NZ742004A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
AU2013255470B2 (en) 2012-05-04 2015-09-17 Novartis Ag Complement pathway modulators and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
IN2015KN00015A (en) 2012-06-18 2015-07-31 Omeros Corp
KR20150033652A (en) 2012-06-20 2015-04-01 노파르티스 아게 Complement pathway modulators and uses thereof
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EA201590118A1 (en) 2012-06-28 2015-04-30 Новартис Аг PYRROLIDINE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF THE COMPLEMENT ACTIVATION
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
CN104619698B (en) 2012-06-28 2016-08-31 诺华股份有限公司 Pyrrolidin derivatives and the purposes as complement pathway regulator thereof
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN105121429B (en) 2012-06-28 2017-12-12 诺华股份有限公司 Complement pathway conditioning agent and its purposes
ITMI20121156A1 (en) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche METHOD OF PROCESSING IMAGES OF TOMOGRAPHY WITH OPTICAL CONSISTENCY
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SI3660033T1 (en) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9773428B2 (en) 2012-12-11 2017-09-26 Fluidity Software, Inc. Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
EP2948480A4 (en) 2013-01-23 2016-12-07 Musc Found For Res Dev Targeting constructs based on natural antibodies and uses thereof
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
MX2016000675A (en) 2013-07-18 2016-05-10 Novartis Ag Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof.
JP2016169161A (en) 2013-07-19 2016-09-23 大日本住友製薬株式会社 Novel imidazo pyridine compound
EA034870B1 (en) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Atypical hemolytic uremic syndrome biomarker proteins
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
AP2016009434A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Amide compounds for treatment of complement mediated disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
EP3386504A4 (en) 2015-12-11 2019-05-22 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3402486A4 (en) 2016-01-14 2019-08-28 ChemoCentryx, Inc. Method of treating c3 glomerulopathy
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
TW202222786A (en) 2016-02-01 2022-06-16 美商百歐克斯製藥公司 Benzopyrazole compounds and analogues thereof
RU2018145364A (en) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. QUINAZOLINE AND INDOLE COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US20190292155A1 (en) 2016-07-15 2019-09-26 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JOP20170154B1 (en) 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ES2933513T3 (en) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Macrocyclic compounds for the treatment of medical disorders
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN111163767A (en) 2017-08-02 2020-05-15 艾其林医药公司 Treatment regimen for paroxysmal nocturnal hemoglobinuria
BR112020006692A2 (en) 2017-10-04 2020-10-06 Alexion Pharmaceuticals, Inc. dosage and administration of anti-c5 antibodies for the treatment of patients with membranoproliferative glomerulonephritis
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
MX2021003425A (en) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN113195472A (en) 2018-12-17 2021-07-30 艾其林医药公司 Targeted drug delivery for the treatment of complement-mediated disorders
CR20220074A (en) 2019-07-31 2022-06-03 Biocryst Pharm Inc Dosing regimens for oral complement factor d inhibitors

Similar Documents

Publication Publication Date Title
AU2022202403A1 (en) Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders
EP3589628A4 (en) Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
HK1257734A1 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
EP3110418A4 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
EP3451895A4 (en) Access devices and methods for treatment of medical conditions and delivery of injectables
EP3589287A4 (en) Macrocyclic compounds for treatment of medical disorders
EP3344325A4 (en) Local administration of drugs for the treatment of asthma
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
EP3841086A4 (en) Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3650860A4 (en) Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases
EP3558281A4 (en) Treatment of mental, movement and behavioral disorders
EP3468540A4 (en) Pharmaceutical compositions and methods for treatment of pain
IL269400A (en) Drugs and compositions for the treatment of ocular disorders
EP3684345A4 (en) Treatment of drug resistant gliomas
EP3661502A4 (en) Compounds for the prevention and treatment of medical disorders and uses thereof
EP3371176A4 (en) Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
EP3713561A4 (en) Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders
HK1259373A1 (en) Pharmaceutical formulations for the treatment of diabetes
EP3338771A4 (en) Pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain
EP3425388A4 (en) Method for assessing pain caused by administration of drug solution, and method for selecting drug solution administration
HUE065421T2 (en) Pharmaceutical composition for nasal administration comprising rifampicins for treating dementia
EP3527217A4 (en) Use of a compound, pharmaceutical composition, and therapeutic method for the treatment or prevention of convulsions
EP3639825A4 (en) Pharmaceutical combination for treatment of fabry disease and use thereof
EP3368512A4 (en) Indoline derivatives for treatment and/or prevention of fibrosis diseases
EP3886848A4 (en) Pharmaceutical compounds and therapeutic methods